Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study

详细信息    查看全文

• 作者：Mirja Gautschi ; MD ; Patrick A. Oberholzer ; MD ; Marc Baumgartner ; MD ; Karolina Gadaldi ; MD ; Nikhil Yawalkar ; MD ; Robert E. Hunger ; MD ; PhD ; ^{robert.hunger@insel.ch" class="auth_mail" title="E-mail the corresponding author}
• 关键词：efficacy ; follow-up ; imiquimod ; lentigo maligna ; prognostic marker ; recurrence ; topical immunomodulators
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：74
• 期：1
• 页码：81-87.e1
• 全文大小：1315 K

文摘

More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM).

Objective

We sought to determine the demographic, clinical, and histologic prognostic markers of relapse-free survival in patients with LM who were treated with imiquimod.

Methods

This was a single-arm, open-label, nonrandomized, prospective study.

Results

Eighty-nine patients with histologically confirmed LM and a median follow-up time of 4.8 years after imiquimod treatment were included in our study. Sixteen patients (18%) relapsed. Statistically significant indicators of an increased risk of local recurrence included: the total number of melanocytes, the number of basal and suprabasal melanocytes and the number of pagetoid spreading melanocytes.

Limitations

Our study was a single-center, nonrandomized study.

Conclusion

An assessment of different melanocyte fractions in the diagnostic baseline biopsy specimen may help to predict the response of LM to imiquimod therapy.